UNHD trade ideas
Be careful with UNHThis descending trendline is problematic. If you bought lower, it may be time to take profits. If you don't have a position, I'd consider shorting the stock and see if you can ride it down to $212 or so.
UNH ShortI think people are being very subjective to the market at this moment. Caution the news coming out. That being said, healthcare sectors from a long term perspective is overbought. I will be shorting UNH for this week. I think there is a good risk reward. I will also be shorting XLV for the long term.
UNHHeld April lows nicely and has broken through some larger timeframe resistance. I like the action here to the upside.
$UNH United Health is still a gift. Entry level $257 = Target price $282 = Stop loss $252
Previous target hit and our reversal trade setup has now rewarded us with 15% gains.
The golden pocket has been broken through so let it rip higher.
UnitedHealth Group looking bullish as well. MMHVWPI - see chart. Institutional support and resistance levels.
UNHSystem T Performances: Annual Compound Profit 40%, Win Rate 55%, Risk Reward 2:1, 20 Years of Backtesting Data! Follow me for my Buy & Sell signals!
Possible short on healthcareSeeing a very consistent dome pattern on the 3D chart. I'd be looking for shorts/puts either on a retest of the dome line or on a break of the support. No trade on this until I one or the other happen.
$UNH Reversal trade off strong support in UnitedHealth Possible entry level $222 = Target price $247 = Stop loss $212
P/E ratio 16.32 which is very reasonable.
Yield 1.98%
Average analyst price target $291 | Buy rating
Latest analyst commentary
Barclays analyst Steven Valiquette maintained a Buy rating on UnitedHealth yesterday and set a price target of $260.00. The company’s shares closed last Monday at $220.11, close to its 52-week low of $208.07.
According to TipRanks.com, Valiquette is a 2-star analyst with an average return of 0.7% and a 47.0% success rate. Valiquette covers the Services sector, focusing on stocks such as AmerisourceBergen Corporation, Patterson Companies Inc, and Capital Senior Living.
Currently, the analyst consensus on UnitedHealth is a Strong Buy with an average price target of $298.45, representing a 35.6% upside. In a report issued on September 26, Morgan Stanley also maintained a Buy rating on the stock with a $294.00 price target.
Sourse Smarter analyst
Company profile
UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health services business serving the broad health care marketplace, including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the health care industry. The OptumRx segment provides pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Minneapolis, MN.
Option traders See reversal trade in UNHToday's options market seen some unusual activity In NYSE:UNH , signalling that there may be some good news on the horizon. The stock has hot some historical support and both the Stoch and RSI are showing signs of a reversal.
UNH insider sales flash a warning sign ahead of earningsUnitedHealth Group has had an incredibly strong showing this year, and right now it's priced pretty attractively at oversold level on the hourly chart. On its daily chart it's at RSI 38, nearing oversold (RSI 30) but not quite there yet. It also hasn't yet tested its August low of 220.78 or its one-year lows of 208.07 and 216.84. I suspect we'll get a bounce tomorrow from the hourly oversold level, then fall some more to the 216-220 range. At that point we should be about oversold on the daily chart and should bounce into earnings on October 15.
The average analyst price target on UNH is about 299, implying about 33% upside from the current price. Analyst estimates of UNH earnings have held steady for the past month at 3.77, significantly better than 3.41 the same quarter last year. UNH has an 8.7/10 Equity Starmine Summary Score rating. So most signs are bullish. However, company director Richard Burke sold 10,000 shares last week. Other directors also recently sold thousands of shares. All this insider selling doesn't inspire confidence for good earnings this quarter. On that basis alone, I don't think I'd hold this for anything more than a pre-earnings bounce. On the other hand, insider sellers may be responding to political risk rather than to the company's financials.
The healthcare sector is expected to report good earnings this quarter, which could make it attractive as a defensive play in an earnings recession. Healthcare is a defensive sector that usually does well when the rest of the market is down. Right now healthcare stocks are cheap, which makes them even more attractive. However, with Elizabeth Warren leading the Democratic pack, UNH's share price may continue its breakdown. Health insurance and pharmaceutical companies are at particular risk from Warren's "Medicare for All" plan, and you may be able to chart healthcare stocks' performance from now until the election as a function of Warren's popularity in the polls.
UNH Bullish Breakout to $250 Into Earnings$UNH is a safety, growth, and value play all in one. Looking for it to continue this upside breakout into earnings. Target is $248
NYSE:UNH
United Healthcare - Buy Signal or Bear Flag?Not financial advice. Do your own research. The ideas shared here are the personal opinions of the BitDoctor team. Trade at your risk.
United Healthcare has been on my radar for a shile but only since last week have I paid more attention to the support we recently had and the pivot we've seen here. I don't speak much to fundamentals, nor do I really care about news events but what I can say is the pivot we recently had is not accidental. It's a technical pivot that we've seen. Indicative of the completion of a 1-2 and then we potentially head up for a much larger 3. I am tempted to go long on UNH from here and stop at the bottom of our pivot. I see we've already closed all gaps and from a moving average standpoint, we're trading below most moving averages. This could be seen as a very bearish setup but as long as this pivot holds ($220), then we should be fine to see a move back to $280 - $300.
Trade carefully friends. If we break $220, then we're almost definitely going back to $200 and likely much lower. I just don't see that right now. I see more upside to $240 minimum. Target, though, is $281.40
<3 -CE-
Several buy signals on UNHI've been watching UNH closely ever since its big guidance upgrade on the last earnings report. The stock chose that moment to start tanking, and it's been tanking ever since. Hopefully the market has now had enough of this down trend and is ready for the stock to recover.
Zacks, one of the best-performing analytics firms, upgraded UNH today to a buy. It's got an 8.3/10 Equity StarMine Summary score. UNH also flashed a buy signal a few days ago on the reverse RSI indicator, and it's in oversold territory on the daily stochastic. There's strong support from volume in the 220-228 range, so this is a good range to buy. Below 220, we could fall to 212 or 200.
